- Details
- Description
LUCISOT (Sotorasib) is a pharmaceutical product containing sotorasib, a targeted anticancer medicine that selectively inhibits the KRAS G12C protein. Sotorasib is designed to block abnormal KRAS G12C signaling, which can contribute to the growth and survival of cancer cells.
Sotorasib is used for the treatment of certain cancers with a confirmed KRAS G12C mutation, including specific cases of locally advanced or metastatic non-small cell lung cancer. Its use depends on the approved indication, molecular testing results, patient condition, and applicable clinical guidelines.
LUCISOT is an oral medicine intended to be used under the supervision of a qualified healthcare professional. The appropriate dosage, treatment duration, monitoring, and management of potential adverse reactions should be determined by the treating physician.
Product strength, packaging, manufacturer, availability, and regulatory status may vary depending on the market and specific product presentation. Healthcare professionals and patients should consult the applicable official prescribing information before use.
